NCT00103558 2015-10-02
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
Biogen
Phase 1/2 Completed
Clinical Trials
5 trialsNCT00391066 2015-10-02
LUCID
Biogen
Phase 2 Terminated
NCT00801060 2015-10-02
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biogen
Phase 2 Terminated
NCT00046488 2013-09-16
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Biogen
Phase 1 Completed
NCT00058396 2013-05-30
Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed